Critical IllnessIPA-ICNCT06714240
Enhanced Protein Intake to Support Muscle Protein Synthesis in ICU
A study testing Nutritionally complete Tube Feed with standard protein levels and Nutritionally complete Tube Feed with higher protein levels in people with Critical Illness and Muscle Protein Synthetic Response to Protein, run by Maastricht University Medical Center at 1 site in Belgium.
Trial summary
Rationale - Critically ill patients often experience severe skeletal muscle wasting due to an imbalance between muscle protein synthesis (MPS) and degradation, contributing to long-term impairments such as ICU-acquired weakness (ICU-AW) and post-intensive care syndrome (PICS). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Critical Illness, Muscle Protein Synthetic Response to Protein
- What is being tested?
- Nutritionally complete Tube Feed with standard protein levels and Nutritionally complete Tube Feed with higher protein levels
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteBelgium
- Study dates
- 1 Sep 2025to Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged ≥ 18 years
- Suitability for enteral nutrition (i.e., no GI failure, absence of complete intestinal obstruction, no major intra-abdominal sepsis)
- Expected mechanical ventilation of minimal three days
- Expected ICU stay of at least seven days
Who cannot join
- BMI ≥ 40 kg/m²
- Spinal cord injury
- Chronic corticosteroid use before hospital admission
- severe allergies or intolerances (e.g., to cow's milk protein, fish, soy, pea protein or galactosemia)
- Severe kidney and/or liver failure
- Requirements for dialysis
- Bleeding disorders, including anticoagulant and antiplatelet therapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Jessa Hospital Campus Virga Jesse
Hasselt, Limburg, 3500
Björn Stessel, Prof. Dr., +3211 33 55 77, bjorn.stessel@jessazh.be
Michèlle Hendriks, MSc, +31 43 388 1184, michelle.hendriks@maastrichtuniversity.nl
About this study
Official title: Increased Protein Amount as a Nutritional Strategy to Enhance Muscle Protein Synthesis in ICU Patients
Rationale - Critically ill patients often experience severe skeletal muscle wasting due to an imbalance between muscle protein synthesis (MPS) and degradation, contributing to long-term impairments such as ICU-acquired weakness (ICU-AW) and post-intensive care syndrome (PICS). Effective interventions to mitigate muscle wasting remain a critical unmet need. Protein intake has been identified as a potential modulator of MPS, but anabolic resistance and conflicting evidence regarding optimal protein intake necessitate further investigation.
Objective/Hypothesis - This study aims to evaluate the effect of a normal (target: 0.8 g protein/kg/day) versus elevated (target: 1.3 g protein/kg/day) protein intake on MPS rates over four days in critically ill patients.
Read more
Population - 26 critically ill patients who are suitable for enteral nutrition, mechanically ventilated (min 3 days), and stay at the ICU for at least 7 days will be included.
Method: Patients are randomly assigned to two groups (normal or higher protein intake). Muscle biopsies and blood samples will be collected to assess muscle protein synthesis rates.
Read the detailed description
Complexities of Critical Illness - Critical illness encompasses the progression of severe medical conditions like major trauma or sepsis, which disrupt the body's homeostasis. This imbalance increases susceptibility to vital organ dysfunction, thereby posing imminent life-threatening consequences without prompt intensive medical support in hospitals. A key concern in critically ill patients is the rapid onset of skeletal muscle wasting, resulting in a condition known as intensive care unit-acquired weakness (ICU-AW). This muscle weakness is closely associated with extended mechanical ventilation and higher morbidity and mortality rates. Even after recovery, patients often suffer from long-term physical impairments and disabilities, resulting in post-intensive care syndrome (PICS), a condition characterized by persistent and debilitating consequences of ICU admission. Muscle weakness can last several years after ICU discharge, contributing to increased healthcare costs and a reduced quality of life. Considering the profound impact on both short- and long-term outcomes, coupled with the absence of effective strategies to prevent muscle wasting and weakness, remain major challenges in modern intensive care medicine.
Skeletal Muscle Protein Imbalance - Skeletal muscle mass is regulated by the balance between muscle protein synthesis, degradation, and folding. Under stable conditions, proteins serve structural and functional purposes crucial for growth, recovery, and adaptation. However, critical illness alters protein dynamics. Disturbance in protein folding can result in the accumulation of damaged proteins, causing a decline in protein quality, while imbalances between protein synthesis and degradation can lead to a decrease in quantity. Critically ill patients often experience a metabolic shift towards a catabolic state, wherein skeletal muscles are broken down to fulfill energy demands. Notably, during this catabolic phase, muscle proteins become a primary fuel source, with rates of muscle protein breakdown surpassing those of synthesis. This rapid muscle protein loss can result in up to 18% reduction in muscle mass within the first 10 days of ICU stay, ultimately leading to muscle atrophy.
Previous research has utilized nitrogen balance assessments and stable isotope techniques to evaluate whole-body protein turnover. However, only a few studies have specifically measured muscle protein synthesis (MPS) rates in critically ill patients using intravenous stable isotope infusions. These measurements typically cover short durations (less than 9 hours), making it challenging to extrapolate the findings to long-term outcomes due to the inherent limitations of amino acid tracer techniques. Adaptions to muscle disuse, inflammation, and catabolic stress likely occur over several days or weeks rather than hours. A promising alternative is oral deuterated water (D2O), which enables the assessment of MPS over longer periods (days or weeks). Current research by our group used D2O to provide insights into muscle synthesis rates over multiple ICU days. This pioneering study will establish critical baseline data for future research.
Protein Ingestion as a Key Modulator - To improve patient recovery, interventions targeting muscle loss are recommended. The 2019 guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) emphasize the importance of nutritional support for mechanically ventilated ICU patients. Specifically, dietary proteins and their amino acid composition are key in mitigating skeletal muscle wasting and improving long-term clinical outcomes. However, the efficacy of dietary protein to stimulate MPS is regulated by various physiological factors such as dietary protein digestion and amino acid absorption, splanchnic amino acid retention, postprandial insulin release, skeletal muscle tissue perfusion, amino acid uptake by muscle, and intramyocellular signaling. Current international guidelines recommend elevated protein intake for critically ill patients, ranging from 1.2 to 2.0 g protein/kg body weight/day, exceeding recommendations for healthy individuals. However, while higher protein intake has been shown to enhance MPS, recent research suggests that the upper threshold of 2.0 g/kg/day may negatively impact health-related quality of life without improving functional outcomes up to 180 days post-ICU admission. Given these conflicting findings, the precise impact of elevated protein intake on MPS in critically ill patients remains unclear, warranting further investigation to determine the optimal protein requirements during critical illness. Furthermore, despite these widely accepted guidelines and intake recommendations, observational studies have reported that actual protein intake in ICU patients often falls below these targets, ranging from 0.7 to 1.2 g/kg/day. Recent research demonstrated efficient digestion and absorption of enterally administered protein. Nevertheless, post-prandial muscle protein synthesis rates were much lower in critically ill patients than in healthy volunteers. This indicates that critical illness does not impair dietary protein digestion and amino acid absorption. However, incorporating dietary protein-derived amino acids into skeletal muscle protein is blunted, representing anabolic resistance to dietary protein. This anabolic resistance underscores the complexity of muscle protein metabolism in critically ill patients and highlights the need for effective strategies to attenuate skeletal muscle wasting.
In short, this prospective study aims to evaluate the effect of normal vs. elevated enteral protein administration on muscle protein synthesis rates and muscle characteristics in critically ill patients. This research will provide valuable insights to develop effective nutritional interventions to address skeletal muscle wasting in critical illness.
- Being tested
- Nutritionally complete Tube Feed with standard protein levels, Nutritionally complete Tube Feed with higher protein levels
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nutritionally complete Tube Feed with standard protein levelsDietary supplement
Containing standard protein levels to target normal protein amount of 0.8 g of protein/kg body weight/day
Nutritionally complete Tube Feed with higher protein levelsDietary supplement
Containing higher protein levels to target elevated protein amount of 1.3 g of protein/kg body weight/day.
| Study group | Role | What they receive |
|---|---|---|
| Normal protein amount | Active comparator | Not described Receives: Dietary Supplement: Nutritionally complete Tube Feed with standard protein levels |
| Elevated protein amount | Experimental | Not described Receives: Dietary Supplement: Nutritionally complete Tube Feed with higher protein levels |
What is being measured
The primary outcome is the main question the study is designed to answer.
Myofibrillar protein fractional synthetic rate
The myofibrillar protein synthesis rates are calculated using D2O.
Measured: 1-4 days
Secondary outcomes (6)
Mixed muscle protein fractional synthetic rate
The mixed muscle protein synthesis rates are calculated using D2O.
Measured: 1-4 days
Plasma amino acids concentrations
Determining differences in plasma amino acids concentration between groups receiving normal versus elevated protein levels through enteral nutrition
Measured: 1-4 days
Muscle fiber size in µm²
Muscle fiber size will be assessed using immunofluorescence staining.
Measured: Final intervention day (after 4 days of enteral feeding)
Proportion (%) of muscle fiber types (type I and type II)
Fiber proportion will be assessed using immunofluorescence staining.
Measured: Final intervention day (after 4 days of enteral feeding)
Myonuclei quantity
Myonuclei quantity will be assessed using immunofluorescence staining.
Measured: Final intervention day (after 4 days of enteral feeding)
Mitochondrial respiration
Mitochondrial respiration will be assessed using Oroboros Instruments (Oroboros O2k FluoRepirometer).
Measured: Final intervention day (after 4 days of enteral feeding)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2024
- Study start1 Sep 2025
- Primary completionOct 2027 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- More trials run by Maastricht University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is a prospective, randomized, longitudinal, controlled interventional trial with a parallel-group design.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Danone Global Research & Innovation Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06714240
- Sponsor's protocol ID
- 2024/223
- Acronym
- IPA-IC
- Status last verified
- Oct 2025
- First submitted
- 20 Nov 2024
- Last updated
- 10 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increased Protein Amount as a Nutritional Strategy to Enhance Muscle Protein Synthesis in ICU Patients
- ClinicalTrials.gov ID
- NCT06714240
- Acronym / sponsor ID
- IPA-IC / 2024/223
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Collaborators
- Danone Global Research & Innovation Center
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 3 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale - Critically ill patients often experience severe skeletal muscle wasting due to an imbalance between muscle protein synthesis (MPS) and degradation, contributing to long-term impairments such as ICU-acquired weakness (ICU-AW) and post-intensive care syndrome (PICS). Effective interventions to mitigate muscle wasting remain a critical unmet need. Protein intake has been identified as a potential modulator of MPS, but anabolic resistance and conflicting evidence regarding optimal protein intake necessitate further investigation.
Objective/Hypothesis - This study aims to evaluate the effect of a normal (target: 0.8 g protein/kg/day) versus elevated (target: 1.3 g protein/kg/day) protein intake on MPS rates over four days in critically ill patients.
Population - 26 critically ill patients who are suitable for enteral nutrition, mechanically ventilated (min 3 days), and stay at the ICU for at least 7 days will be included.
Method: Patients are randomly assigned to two groups (normal or higher protein intake). Muscle biopsies and blood samples will be collected to assess muscle protein synthesis rates.
Detailed description
Complexities of Critical Illness - Critical illness encompasses the progression of severe medical conditions like major trauma or sepsis, which disrupt the body's homeostasis. This imbalance increases susceptibility to vital organ dysfunction, thereby posing imminent life-threatening consequences without prompt intensive medical support in hospitals. A key concern in critically ill patients is the rapid onset of skeletal muscle wasting, resulting in a condition known as intensive care unit-acquired weakness (ICU-AW). This muscle weakness is closely associated with extended mechanical ventilation and higher morbidity and mortality rates. Even after recovery, patients often suffer from long-term physical impairments and disabilities, resulting in post-intensive care syndrome (PICS), a condition characterized by persistent and debilitating consequences of ICU admission. Muscle weakness can last several years after ICU discharge, contributing to increased healthcare costs and a reduced quality of life. Considering the profound impact on both short- and long-term outcomes, coupled with the absence of effective strategies to prevent muscle wasting and weakness, remain major challenges in modern intensive care medicine.
Skeletal Muscle Protein Imbalance - Skeletal muscle mass is regulated by the balance between muscle protein synthesis, degradation, and folding. Under stable conditions, proteins serve structural and functional purposes crucial for growth, recovery, and adaptation. However, critical illness alters protein dynamics. Disturbance in protein folding can result in the accumulation of damaged proteins, causing a decline in protein quality, while imbalances between protein synthesis and degradation can lead to a decrease in quantity. Critically ill patients often experience a metabolic shift towards a catabolic state, wherein skeletal muscles are broken down to fulfill energy demands. Notably, during this catabolic phase, muscle proteins become a primary fuel source, with rates of muscle protein breakdown surpassing those of synthesis. This rapid muscle protein loss can result in up to 18% reduction in muscle mass within the first 10 days of ICU stay, ultimately leading to muscle atrophy.
Previous research has utilized nitrogen balance assessments and stable isotope techniques to evaluate whole-body protein turnover. However, only a few studies have specifically measured muscle protein synthesis (MPS) rates in critically ill patients using intravenous stable isotope infusions. These measurements typically cover short durations (less than 9 hours), making it challenging to extrapolate the findings to long-term outcomes due to the inherent limitations of amino acid tracer techniques. Adaptions to muscle disuse, inflammation, and catabolic stress likely occur over several days or weeks rather than hours. A promising alternative is oral deuterated water (D2O), which enables the assessment of MPS over longer periods (days or weeks). Current research by our group used D2O to provide insights into muscle synthesis rates over multiple ICU days. This pioneering study will establish critical baseline data for future research.
Protein Ingestion as a Key Modulator - To improve patient recovery, interventions targeting muscle loss are recommended. The 2019 guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) emphasize the importance of nutritional support for mechanically ventilated ICU patients. Specifically, dietary proteins and their amino acid composition are key in mitigating skeletal muscle wasting and improving long-term clinical outcomes. However, the efficacy of dietary protein to stimulate MPS is regulated by various physiological factors such as dietary protein digestion and amino acid absorption, splanchnic amino acid retention, postprandial insulin release, skeletal muscle tissue perfusion, amino acid uptake by muscle, and intramyocellular signaling. Current international guidelines recommend elevated protein intake for critically ill patients, ranging from 1.2 to 2.0 g protein/kg body weight/day, exceeding recommendations for healthy individuals. However, while higher protein intake has been shown to enhance MPS, recent research suggests that the upper threshold of 2.0 g/kg/day may negatively impact health-related quality of life without improving functional outcomes up to 180 days post-ICU admission. Given these conflicting findings, the precise impact of elevated protein intake on MPS in critically ill patients remains unclear, warranting further investigation to determine the optimal protein requirements during critical illness. Furthermore, despite these widely accepted guidelines and intake recommendations, observational studies have reported that actual protein intake in ICU patients often falls below these targets, ranging from 0.7 to 1.2 g/kg/day. Recent research demonstrated efficient digestion and absorption of enterally administered protein. Nevertheless, post-prandial muscle protein synthesis rates were much lower in critically ill patients than in healthy volunteers. This indicates that critical illness does not impair dietary protein digestion and amino acid absorption. However, incorporating dietary protein-derived amino acids into skeletal muscle protein is blunted, representing anabolic resistance to dietary protein. This anabolic resistance underscores the complexity of muscle protein metabolism in critically ill patients and highlights the need for effective strategies to attenuate skeletal muscle wasting.
In short, this prospective study aims to evaluate the effect of normal vs. elevated enteral protein administration on muscle protein synthesis rates and muscle characteristics in critically ill patients. This research will provide valuable insights to develop effective nutritional interventions to address skeletal muscle wasting in critical illness.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The study is a prospective, randomized, longitudinal, controlled interventional trial with a parallel-group design.
| Arm | Type | Receives |
|---|---|---|
| Normal protein amount | Active comparator | Dietary Supplement: Nutritionally complete Tube Feed with standard protein levels |
| Elevated protein amount | Experimental | Dietary Supplement: Nutritionally complete Tube Feed with higher protein levels |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Aged ≥ 18 years
- Suitability for enteral nutrition (i.e., no GI failure, absence of complete intestinal obstruction, no major intra-abdominal sepsis)
- Expected mechanical ventilation of minimal three days
- Expected ICU stay of at least seven days
Key exclusion criteria (7 listed)
- BMI ≥ 40 kg/m²
- Spinal cord injury
- Chronic corticosteroid use before hospital admission
- severe allergies or intolerances (e.g., to cow's milk protein, fish, soy, pea protein or galactosemia)
- Severe kidney and/or liver failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nutritionally complete Tube Feed with standard protein levelsContaining standard protein levels to target normal protein amount of 0.8 g of protein/kg body weight/day | Dietary supplement | Normal protein amount |
| Nutritionally complete Tube Feed with higher protein levelsContaining higher protein levels to target elevated protein amount of 1.3 g of protein/kg body weight/day. | Dietary supplement | Elevated protein amount |
Primary outcome
Myofibrillar protein fractional synthetic rate
Time frame: 1-4 days
The myofibrillar protein synthesis rates are calculated using D2O.
6 secondary outcomes
Mixed muscle protein fractional synthetic rate
Time frame: 1-4 days
Plasma amino acids concentrations
Time frame: 1-4 days
Muscle fiber size in µm²
Time frame: Final intervention day (after 4 days of enteral feeding)
Proportion (%) of muscle fiber types (type I and type II)
Time frame: Final intervention day (after 4 days of enteral feeding)
Myonuclei quantity
Time frame: Final intervention day (after 4 days of enteral feeding)
Mitochondrial respiration
Time frame: Final intervention day (after 4 days of enteral feeding)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Critical Illness
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Active, not recruiting
Weighted Blankets for Agitation in Adults in the Intensive Care Unit
Psychomotor Agitation, Critical Illness
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nutritionally complete Tube Feed with standard protein levels and Nutritionally complete Tube Feed with higher protein levels in people with Critical Illness and Muscle Protein Synthetic Response to Protein, run by Maastricht University Medical Center at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michèlle Hendriks, MSc (+31 43 388 1184, michelle.hendriks@maastrichtuniversity.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Myofibrillar protein fractional synthetic rate (time frame: 1-4 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.